Increased PUFA levels in kidney epithelial cells in the course of diclofenac toxicity

AYDIN ASLAN M., KIRIMLIOĞLU E., Afsar E., ÇEKER T., YILMAZ C.

TOXICOLOGY IN VITRO, cilt.66, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 66
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.tiv.2020.104836
  • Dergi Adı: TOXICOLOGY IN VITRO
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, CAB Abstracts, EMBASE, Environment Index, MEDLINE, Veterinary Science Database
  • Anahtar Kelimeler: Diclofenac, Kidney cells, Thymoquinone, Polyunsaturated fatty acids, NONSTEROIDAL ANTIINFLAMMATORY DRUGS, FATTY-ACIDS, ARACHIDONIC-ACID, ACUTE PAIN, THYMOQUINONE, NEUROBLASTOMA, INFLAMMATION, MECHANISM, SODIUM, CYCLOOXYGENASE-2
  • Akdeniz Üniversitesi Adresli: Evet

Özet

This study evaluated polyunsaturated fatty acids (PUFAs) in human kidney epithelial cells exposed to diclofenac (DCL) toxicity. Kidney cells were treated with DCL to induce cytotoxicity and thymoquinone (TQ) was administered to decrease cytotoxic effects. Levels of arachidonic acid (AA, C20:4n-6), dihomo-gamma-linolenic acid (DGLA, C20:3n-6), eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3) were determined by liquid chromatography coupled with tandem mass spectrometry. Cytosolic phospholipase A(2) (cPLA(2)), cyclooxygenase 1 (COX-1) and prostaglandin E-2 (PGE(2)) were measured to evaluate changes in enzyme activity. Immunofluorescence staining and western blot analysis was performed to determine protein levels of COX- 1. Renal cell toxicity was accomplished by DCL and was alleviated by TQ treatment. Diclofenac significantly increased all measured PUFAs while pretreatment with TQ decreased PUFA levels in DCL treated cells. Cytosolic PLA(2) and total COX activity was significantly decreased in DCL treated cells. Immunofluorescence staining and western blot analysis confirmed significantly decreased COX-1 levels in DCL and DCL + TQ treated groups. The results of this study reveal that DCL treatment is associated with accumulation of PUFAs in kidney cells. We suggest that PUFA accumulation in DCL toxicity might be a consequence of both cPLA(2) and COX-1 inhibition. Thymoquinone administration, along with DCL treatment alleviated the buildup of PUFAs and DCL-induced cell death in kidney cells.